These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 30146910)

  • 1. Microbial modulation of the gut microbiome for treating autoimmune diseases.
    Balakrishnan B; Taneja V
    Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):985-996. PubMed ID: 30146910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Microbiome and Antibiotics in Autoimmune Diseases.
    Vangoitsenhoven R; Cresci GAM
    Nutr Clin Pract; 2020 Jun; 35(3):406-416. PubMed ID: 32319703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota in autoimmunity: potential for clinical applications.
    Kim D; Yoo SA; Kim WU
    Arch Pharm Res; 2016 Nov; 39(11):1565-1576. PubMed ID: 27444041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The microbiome in autoimmune diseases.
    De Luca F; Shoenfeld Y
    Clin Exp Immunol; 2019 Jan; 195(1):74-85. PubMed ID: 29920643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes.
    Ganesan K; Chung SK; Vanamala J; Xu B
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30467295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal dysbiosis and probiotic applications in autoimmune diseases.
    de Oliveira GLV; Leite AZ; Higuchi BS; Gonzaga MI; Mariano VS
    Immunology; 2017 Sep; 152(1):1-12. PubMed ID: 28556916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gut microbiota: What impact on colorectal carcinogenesis and treatment?].
    Bruneau A; Baylatry MT; Joly AC; Sokol H
    Bull Cancer; 2018 Jan; 105(1):70-80. PubMed ID: 29217301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging diet to engineer the gut microbiome.
    Wolter M; Grant ET; Boudaud M; Steimle A; Pereira GV; Martens EC; Desai MS
    Nat Rev Gastroenterol Hepatol; 2021 Dec; 18(12):885-902. PubMed ID: 34580480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the gut microbiome in cardiovascular and autoimmune diseases.
    Weis M
    Clin Sci (Lond); 2018 Nov; 132(22):2387-2389. PubMed ID: 30455339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity.
    Meng X; Zhou HY; Shen HH; Lufumpa E; Li XM; Guo B; Li BZ
    Autoimmun Rev; 2019 May; 18(5):455-475. PubMed ID: 30844549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiome.
    Sidhu M; van der Poorten D
    Aust Fam Physician; 2017; 46(4):206-211. PubMed ID: 28376573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the gut microbiome in systemic inflammatory disease.
    Clemente JC; Manasson J; Scher JU
    BMJ; 2018 Jan; 360():j5145. PubMed ID: 29311119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases.
    Marietta E; Mangalam AK; Taneja V; Murray JA
    Front Immunol; 2020; 11():573079. PubMed ID: 33193357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered.
    Qiao YQ; Cai CW; Ran ZH
    J Dig Dis; 2016 Dec; 17(12):800-810. PubMed ID: 27743467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation probiotics: an overview of the most promising candidates.
    Dudík B; Kiňová Sepová H; Greifová G; Bilka F; Bílková A
    Epidemiol Mikrobiol Imunol; 2022; 71(1):48-56. PubMed ID: 35477270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic and Modulation of Microbiota: A New Paradigm?
    Rizzatti G; Ianiro G; Gasbarrini A
    J Clin Gastroenterol; 2018; 52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017():S74-S77. PubMed ID: 29912755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.